Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy

Antiviral Therapy

Volumn 11, Issue 7, 2006, Pages 931-934

  Saitta, Carlo ^a   Pontisso, Patrizia ^b   Brunette, Maurizia R ^c   Fargion, Silvia ^d   Gaeta, Giovanni B ^e   Niro, Grazia A ^f   Picciotto, Antonio ^g   Smedile, Antonina ^h   Squadrito, Giovanni ^a   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIREMIA; VIROLOGY;

EID: 33750943792     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965350601100713     Document Type: Article

References (22)

1. Fong T-L, Di Bisceglie AM, Waggoner Jg, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14:64-67.
2. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22:1101-1108.
3. Sagnelli E, Coppola N, Scolastico C, et al. Virological and clinical aspects of reciprocal inhibitory effect of hepatitis B, C, and Delta viruses in patients with chronic hepatitis. Hepatology 2000; 32:1106-1110.
4. Simonetti RG, Cammà G, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992; 116:97-102.
5. Benvegnù L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994; 74:2442-2448.
6. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132-2137.
7. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36:S74-S83.
8. Raimondo G, Caccamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 2005; 4:100-106.
9. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36:S226-S236.
10. Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995; 22 Suppl 1:38-41.
11. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Hu-H7 cells. J Virol 1993; 67:5823-5832.
12. Shih CM, Chen CM, Chen SY, Lee YH. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995; 69:1160-1171.
13. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37:855-862.
14. Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278:591-607.
15. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43:100-107.
16. Villa E, Grottola A, Trande P, et al. Reactivation of hepatitis B virus infection induced by Interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet 1993; 341:1413.
17. Liu CJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and Interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37:568-576.
18. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B,C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2:39-45.
19. Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastoenterol 1999; 94:2246-2250.
20. Villa E, Grottola A, Buttafoco P, et al. High doses of a-Interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long-term results of a prospective randomized trial. Am J Gastroenterol 2001; 96:2973-2977.
21. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013.
22. Janssen HL, Zonneveld M, Senturk H, et al. Pegylated Interferon alpha-2b alone or in combination with Lamivudine for HBeAg positive chronic hepatitis B: a randomised trials. Lancet, 2005; 365:123-129.